新诺威：关于控股子公司度普利尤单抗注射液获得药物临床试验批准通知书的公告

Core Viewpoint - The company XinNuoWei announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - The approval pertains to the clinical trial notification for Dupilumab injection [1] - The clinical trials are expected to begin in the near future [1]